Skip to main content

Table 2 Data extraction form

From: Immunotherapy with check-point inhibitors (CPI) in adult malignancies: a protocol for the systematic review of the quality of economic analyses

Variable name Allowable values Explanation
Baseline trial characteristics
ID Valid PubMed ID number Pubmed ID
Journal Name of journal Journal of publication
Year 2007–2018 Year of publication
Tumor site Non-small cell lung cancer Melanoma Renal cell carcinoma Squamous cell carcinoma of the head and neck Urothelial carcinoma Classical Hodgkin lymphoma Other The tumor type for which treatment with a check-point inhibitor was analyzed.
Check_point_1 Nivolumab Name of the first check-point inhibitor being compared.
Pembrolizumab
Atezolizumab
Avelumab
Durvalumab
Ipilimumab
Tremelimumab
Check_point_2 Nivolumab Name of 2nd check-point inhibitor being compared, if applicable.
Pembrolizumab
Atezolizumab
Avelumab
Durvalumab
Ipilimumab
Tremelimumab
Comparator_1 Placebo Name of the 1st non-check-point-inhibitor agent or chemotherapeutic regimen being compared, if applicable.
Name of other agent or regimen
Comparator_2 Placebo Name of the 2nd non-check-point-inhibitor agent or chemotherapeutic regimen being compared, if applicable.
Name of other agent or regimen
Funding Industry/government Funding source declared by article
Country List of country names List of all the countries in which the economic analysis applied as reported by the article.
Multiple_countries Y/N Did the economic analysis apply to multiple countries?
CHEERS criteria
Title C/I As detailed in CHEERS recommendations [9]
Abstract C/PC/I As detailed in CHEERS recommendations [9]
Background & Objectives C/PC/I As detailed in CHEERS recommendations [9]
Target population C/PC/I As detailed in CHEERS recommendations [9]
Setting_Location C/PC/I As detailed in CHEERS recommendations [9]
Perspective C/PC/I As detailed in CHEERS recommendations [9]
Comparators C/PC/I As detailed in CHEERS recommendations [9]
Time horizon C/PC/I As detailed in CHEERS recommendations [9]
Discount rate C/PC/I As detailed in CHEERS recommendations [9]
Health outcomes C/PC/I As detailed in CHEERS recommendations [9]
Effectiveness C/PC/I As detailed in CHEERS recommendations [9]
Preference for outcomes C/PC/I/NA As detailed in CHEERS recommendations [9]
Resources and cost C/PC/I As detailed in CHEERS recommendations [9]
Resource quantities C/PC/I As detailed in CHEERS recommendations [9]
Choice of model C/PC/I As detailed in CHEERS recommendations [9]
Assumptions C/PC/I As detailed in CHEERS recommendations [9]
Analytic methods C/PC/I As detailed in CHEERS recommendations [9]
Study parameters C/PC/I As detailed in CHEERS recommendations [9]
ICERs C/PC/I As detailed in CHEERS recommendations [9]
Uncertainty C/PC/I As detailed in CHEERS recommendations [9]
Heterogeneity C/PC/I/NA As detailed in CHEERS recommendations [9]
Limitations C/PC/I As detailed in CHEERS recommendations [9]
Funding source C/I As detailed in CHEERS recommendations [9]
Conflict of Interest C/I As detailed in CHEERS recommendations [9]
  1. C complete; PC partially complete; I incomplete; NA not applicable